Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akira Hamada

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Lung Cancer (Amsterdam, Netherlands)|November 6, 2021
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trialAkira Hamada, Kenichi Suda, Takamasa Koga, et al.
Surgery Today|May 16, 2020
Prognostic value of plasma fibrinogen and D-dimer levels in patients with surgically resected non-small cell lung cancerShuta Ohara, Kenichi Suda, Kenji Tomizawa, et al.
Translational Lung Cancer Research|November 19, 2020
Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot studyShuta Ohara, Kenichi Suda, Kazuko Sakai, et al.
General Thoracic and Cardiovascular Surgery|July 15, 2026
Real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapyTakaki Akamine, Kazuki Hayasaka, Kazuki Takada, et al.
Cells|September 13, 2025
Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon <i>EGFR</i> Mutations-An In Vitro StudyHana Oiki, Kenichi Suda, Akira Hamada, et al.
Cancer Research Communications|November 19, 2025
Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor AppearanceKenichi Suda, Yukihiro Yoshida, Hidenori Sato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 10, 2021
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro ExperimentsTakamasa Koga, Kenichi Suda, Toshio Fujino, et al.
JTO Clinical and Research Reports|September 8, 2023
Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug TestingTakamasa Koga, Junichi Soh, Akira Hamada, et al.
Surgical Case Reports|June 28, 2019
Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosisShuta Ohara, Kenji Tomizawa, Shigeki Shimizu, et al.
JTO Clinical and Research Reports|May 16, 2022
Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLCAkira Hamada, Kenichi Suda, Toshio Fujino, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Lung Cancer (Amsterdam, Netherlands)|November 6, 2021
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trialAkira Hamada, Kenichi Suda, Takamasa Koga, et al.
Surgery Today|May 16, 2020
Prognostic value of plasma fibrinogen and D-dimer levels in patients with surgically resected non-small cell lung cancerShuta Ohara, Kenichi Suda, Kenji Tomizawa, et al.
Translational Lung Cancer Research|November 19, 2020
Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot studyShuta Ohara, Kenichi Suda, Kazuko Sakai, et al.
General Thoracic and Cardiovascular Surgery|July 15, 2026
Real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapyTakaki Akamine, Kazuki Hayasaka, Kazuki Takada, et al.
Cells|September 13, 2025
Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon <i>EGFR</i> Mutations-An In Vitro StudyHana Oiki, Kenichi Suda, Akira Hamada, et al.
Cancer Research Communications|November 19, 2025
Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor AppearanceKenichi Suda, Yukihiro Yoshida, Hidenori Sato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 10, 2021
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro ExperimentsTakamasa Koga, Kenichi Suda, Toshio Fujino, et al.
JTO Clinical and Research Reports|September 8, 2023
Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug TestingTakamasa Koga, Junichi Soh, Akira Hamada, et al.
Surgical Case Reports|June 28, 2019
Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosisShuta Ohara, Kenji Tomizawa, Shigeki Shimizu, et al.
JTO Clinical and Research Reports|May 16, 2022
Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLCAkira Hamada, Kenichi Suda, Toshio Fujino, et al.
Pageof 9